Slide 1: The new standard in digital pathology and precision surgery
For personal use only The new standard in digital pathology and precision surgery. Optiscan Imaging Ltd. (ASX:OIL) Investor Update 4 December 2025
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) on 4 December 2025 and approved for market release by the Board of Optiscan. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain
Slide 3: Dr Camile Farah, CEO & Managing Director
For personal use only Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director Optiscan Imaging Ltd (ASX:OIL) ceo@optiscan.com /company/Optiscan www.optiscan.com
Slide 4: We see what others don't
We see what others don’t Optiscan - a global medical technology company leading the transformation of digital pathology and precision surgery For personal use only ASX: OIL Melbourne $120m Patent Proven Validated Team 2,350 m2 QMS Minnesota 1997 Headquarters Market Cap Protected Technology Products
Slide 5: From bottleneck to breakthrough
From bottleneck to breakthrough For personal use only • Every field of medicine relies on pathology — yet it remains analogue, slow, and reactive. • Surgeons operate partly blind, without real-time tissue assessment. • Repeat procedures and delayed results create risk, overload hospitals, and create
Slide 6: From bottleneck to breakthrough
From bottleneck to breakthrough Imagine pathology that’s real-time, digital, and at the point of care! For personal use only Imagine doctors diagnosing conditions on the spot without physical biopsies! Imagine surgeons treating cancers completely first time, every time! Imagine pathologists seeing c
Slide 7: Clarity no one else can deliver
Clarity no one else can deliver Invasive Breast Cancer • Unique capability: See living cells in the body, in real time, with resolution >1000x CT/MRI. H&E CLE For personal use only • Digital-native advantage: No slides, no processing, no delays - fully aligned with healthcare’s shift to digital and
Slide 8: One technology, many markets
One technology, many markets For personal use only • Medical: real-time surgery, digital pathology, robotic integration. • Veterinary: oncology, minimally invasive procedures, point of care. • Telepathology and AI/ML: remote consultation, digital workflows, decision support. • Life sciences: live, l
Slide 9: From invention to commercialisation
From invention to commercialisation Optiscan is on a transformation journey; from OEM to pure play digital solutions provider. Optiscan now sits at a significant juncture; crossing from product development to commercial adoption. For personal use only Phase 1: Phase 2: Phase 3: Core foundation S
Slide 10: 2025 – A year of convergence
2025 – A year of convergence 2025 marked a pivotal point in Optiscan’s journey — the year our For personal use only technology, partnerships, and clinical programs came together to advance from development to validation. Why it matters Every milestone achieved this year was part of a deliberate stra
Slide 11: Significant milestones 2025
Significant milestones 2025 Key Achievements 2025 For personal use only Finance $1.775 R&D Tax Refund January 2025 Refund strengthens Optiscan’s balance sheet and supports continued investment in product development and clinical programs. Clinical GI Study in Germany initiated with First Prototype F
Slide 12: Significant milestones 2025
Significant milestones 2025 Key Achievements 2025 For personal use only Partnership Agreement Signed with Long Grove Pharmaceuticals June 2025 An exclusive collaboration agreement to develop new intended uses for Long Grove’s intravenous fluorescein sodium contrast agent (AK-FLOUR®). Clinical Breast
Slide 13: The next era of medicine
The next era of medicine Clinical Device Family Vision For personal use only + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecul
Slide 14: The next era of medicine
The next era of medicine Clinical Device Family Vision For personal use only + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecul
Slide 15: Devices with impact
Devices with impact ViewnVivo® InSpecta InVivage® InVue® InForm (Life Sciences) (Veterinary) (Oral) (Surgery) (Pathology) For personal use only Clinical Testing & Regulatory Submissions Underway
Slide 16: The next era of medicine
The next era of medicine Clinical Device Family Vision For personal use only + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecul
Slide 17: Telepathology live streaming
Telepathology live streaming For personal use only
Slide 18: The next era of medicine
The next era of medicine Clinical Device Family Vision For personal use only + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecul
Slide 19: AI-Assist solutions
AI-Assist solutions Oral Breast GI For personal use only Instantaneous diagnostic capability of pre-cancer and cancer with AI solutions for oral, breast and GI pathology
Slide 20: The next era of medicine
The next era of medicine Clinical Device Family Vision For personal use only + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecul
Slide 21: GI flexible scope concept design
GI flexible scope concept design For personal use only
Slide 22: The next era of medicine
The next era of medicine Clinical Device Family Vision For personal use only + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecul
Slide 23: Robotic integration
For personal use only Robotic integration
Slide 24: Product pipeline
Product pipeline Application Stage Collaborators use only InSpecta - Veterinary CLINICAL REGULATORY LAUNCH IDEATION PROTOTYPING PRECLINICAL MONITORING 2025-2026 2026 2026 InVue® - Surgical IDEATION PROTOTYPING PRECLINICAL CLINICAL 2025-2026 REGULATORY 2026 LAUNCH 2027 MONITORING Hardware InForm - Pa
Slide 25: Key financial information
Key financial information Shareholders FY2025 Financial Information For personal use only Revenue $0.95m EBITDA ($5.84m) Total Assets $10.55m 25.5% Total Liabilities $2.84m 37% 18.8% As of 30 Sep 2025 18.7% Cash $19.99m* Top 20 shareholders: 74.5% Capital raised $17.75m *Unaudited Peters Investments
Slide 26: Commercialisation growth stages
Commercialisation growth stages 2028+ For personal use only Market opportunity 2027 a) Surgery-Robotics: $3.92B b) Oral Imaging: $1.9B Market opportunity 2026 a) Surgery-Open(Breast and c) GI: $185B Head & Neck): $30B Market opportunity b) Pathology: $35.1B Notes: 2025 Veterinary market: $46.51B Not
Slide 27: Growth opportunities
Growth opportunities >$100B market opportunity For personal use only Veterinary Surgery Pathology InSpecta InVue® InForm
Slide 28: Veterinary market
Veterinary market InSpecta For personal use only ASPECT P A S T ( P R E - 2 01 5 ) P R E S E NT & F U T U R E ( 2 0 2 5 + ) Care Model Reactive, walk-in Hybrid, proactive, digital-first Technology Use Minimal AI, wearables, telehealth, 3D printing Revenue Model Fee-for-service Subscription, wellness
Slide 29: Surgery market
Surgery market InVue® For personal use only MODERN – MINIMALLY INVASIVE & METRIC T R A D I TI O N A L - O P E N S U R G E R Y R O B O TI C Incision Size Large Small (laparoscopic) or micro (robotic) Recovery Time Longer (weeks) Shorter (days to a week) Hospital Stay 5–10 days 1–3 days (robotic often
Slide 30: Pathology market
Pathology market InForm For personal use only METRIC T R A D I TI O N A L P A T H O L O G Y DIGITAL PATHOLOGY Turnaround Time Slow due to manual handling Up to 50% faster with digital & AI Cost Low upfront, high operational High initial, long-term savings Market Opportunity (US) Mature market USD $1
Slide 31: Gastrointestinal (GI) market
Gastrointestinal (GI) market GI Flexible Device For personal use only METRIC T R A D I TI O N A L G I P R A C TI C E S M O D E R N G I P R A C T I C ES Manual endoscopy, X-rays, barium AI-assisted colonoscopy, capsule endoscopy, Technology studies molecular imaging General treatment protocols, sympt
Slide 32: Scalable business model
Scalable business model Revenue model: • Hardware – devices sold into clinics, For personal use only hospitals, pathology labs and veterinary practices. CAPEX – High gross margins. • Software – SaaS subscription revenue from telepathology and AI/ML solutions. • Consumables - recurring revenue from s
Slide 33: Positioned for growth
Positioned for growth Building on Momentum For personal use only • 2025 marked a pivotal year as Optiscan transitioned from development to clinical validation. • 2026 will see this momentum accelerate, with a focus on commercial readiness and global expansion across veterinary and clinical markets.
Slide 34: A category-defining opportunity
A category-defining opportunity This is the leap from analogue to digital, from delay to immediacy - and For personal use only Optiscan is making it possible. • Revolutionary technology - the only platform delivering high resolution, real-time, sub-cellular, live microscopic imaging. • Multi-market
Slide 35: Thank you for your attendance
For personal use only THANK YOU FOR YOUR ATTENDANCE
Slide 36: Dr Camile Farah, CEO & Managing Director
For personal use only Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director Optiscan Imaging Ltd (ASX:OIL) ceo@optiscan.com /company/Optiscan www.optiscan.com
Slide 37: For personal use only
O Optiscan Ajuo asn yeuossad 104